(MENAFN- ProactiveInvestors - N.America) Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is heading towards one of the year's largest US corporate bond deals as foreign investors stampeded for a piece of the high quality paper.
The Israeli group, which will use the proceeds to fund its acquisition of Allergan's (NYSE:AGN) generic drug business, counted orders of $70bn for a bond sale of between $14bn and $16bn.
If completed at the high end of expectations, the transaction would rank as the year's third-largest corporate bond deal, behind a $46bn sale by Anheuser-Busch InBev and a $20bn offering from computer maker Dell (NASDAQ:DELL).
Teva's ADRs were changing hands at $52.04, down 0.32%, on Monday.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.